HSC Section 8_April 2017

Ajalloueyan (2006) 19 RCS 108 – ? ? 1 6 1 M – – 1 – 6 L

Brown (1982) 6 RCS 1142 – ? ? 6 6 1 M – – 1 – – L Roden (1996) 18 RCS 97 1 ? – 6 1 – M – 6 – 6 6 L

Stankovic (2007) 15 PCS 758 – ? ? 6 1 6 M 1 1 6 – 6 M Declerck (2010) 4 RCS 161 1 1 ? 6 1 6 H – 6 – 1 – L

Nyrop (1997) 7 RCS 85 – 1 ? 6 6 6 M 6 – 6 1 1 M

Charachon (1980) 17 RCS 211 – ? ? 6 – 1 L 1 – 6 6 – M *Priority items.

Palmgren (1979) 20 RCS 347 – ? ? – 6 1 M 1 – 6 6 – M

Rel. Val. Age* Acquired First Charact. Disease* FU Duration* to FU* by Indication*

Loss to follow-up: 1 5 20%; 6 5 > 20%; 2 5 not available. Missing data: 1 5 reported and quantified, method of handling described; 6 5 reported and quantified, method of handling not described; 2 5 not reported. Information Bias Standardization determinant: 1 5 according to protocol, well described; 6 5 according to protocol; – 5 no protocol. Standardization outcome: 1 5 according to protocol, well described; 6 5 according to protocol; 2 5 no protocol. Confounding Confounding by indication: 1 5 no confounding by indication; 6 5 confounding present but well documented; 2 5 confounding poorly documented. Overall Relevance 1 5 1 point; 6 5 0.5 point; 2 or ? 5 0 points. For priority items: 1 5 2 points; 6 5 1 point; 2 or ? 5 0 points. L 5 0–2.5 points; M 5 3–5.5 points; H 5 6 points. Overall Validity 1 5 1 point; 6 5 0.5 point; 2 or ? 5 0 points. For priority items: 1 5 2 points; 6 5 1 point; 2 or ? 5 0 points. L 5 0–2.5 points; M 5 3–5.5 points; H 5 6 points

Age: 1 5 only adults ( 18 years old) included; – 5 also adolescents (14–17 years old) included. Acquired: 1 5 only acquired cholesteatoma mentioned; – 5 acquired and congenital; ? 5 not reported. First: 1 5 primary surgery only; – 5 reoperations included; ? 5 not reported. Baseline characteristics: 1 5 complete and equally distributed; 6 5 incomplete or unequally distributed; – 5 absent. Outcome Recurrent/residual disease: 1 5 reported separately; 6 5 combined data; – 5 only data of residual disease. Follow-up duration: 1 5 > 5 years; 6 5 2 2 5 years; – 5 < 2 years. Selection Bias

Confounding

Confounding

Legend: charact. 5 characteristics; CWU 5 canal wall up; CWD 5 canal wall down; FU 5 follow-up; H 5 high; L 5 low; M 5 moderate; No. 5 number of patients; PCS 5 prospective cohort study; RCS 5 retrospective cohort study; Rel. 5 relevance; Val. 5 validity. Domain

Standardization Outcome

Selection Bias Information bias Missing Data*

Standardization Determinant

Loss

TABLE I.

Domain Outcome

Recurrent/ Residual

Baseline

Study Assessment of Studies Comparing Recurrence Rates Between the CWU Technique and the CWD Technique.

(publication year) Design No.

Author

Laryngoscope 126: April 2016

Kerckhoffs et al.: A Review on Cholesteatoma Recidivism After CWU and CWD

107